A New Chapter for CV Risk Management in Diabetes - Challenges & Opportunities

Introduction/Overview

T2DM as a Risk Factor for CVD

Mortality and CVD in T2DM: Data From the Swedish Registry Study

Close Linkage Between T2DM and HF

T2DM and Patients at CV Risk: Many Targets but Questionable Success

A Correlation Exists Between HF and T2DM

December 2008 FDA Guidance on Evaluating CV Risk in New Antidiabetic Therapies for T2DM

SAVOR-TIMI, EXAMINE, TECOS: Topline Results

EMPA-REG: Primary Outcome (3-point MACE): CV Death, Nonfatal MI, or Nonfatal Stroke

EMPA-REG: Results for CV Death

Key Outcome of EMPA-REG (but not to be Found in the Published Papers)

Potential Mechanisms for CV Benefit Associated With Empagliflozin

HF Improvement: Differential Volume Regulation by SGLT2 Inhibitors vs Loop Diuretics

The "Fuel Hypothesis" as Explanation of Empagliflozin's Cardiorenal Benefits

Glucose and Body Weight Reduction Associated With SGLT2 Inhibitors

The Importance of Addressing CVD in the Context of T2DM

Kidney Damage and SGLT2 Inhibitors

GLP-1 RAs and SGLT2 Inhibitors: Anti-Glycemic Agents or CV Drugs?

ELIXA: Primary Outcome: CV Death, Nonfatal MI, Nonfatal Stroke, or Hospitalization for Unstable Angina

LEADER: Primary Outcome*

LEADER: CV Death

SUSTAIN-6 (Semaglutide): Primary Outcome Results

LEADER Subgroup Analysis: Effect of Liraglutide on Patients With T2DM and Polyvascular Disease

Benefit of Empagliflozin in Patients With HF?

Clear-Cut Clinical Roles for Empagliflozin and Liraglutide Based on Different MOAs

New Paradigm for Treating the Patient With Both T2DM and CVD

Hypothetical Trial: Combination of GLP-1 RA and SGLT2 Inhibitor With CV Endpoints

Linkage Between Elevated Glucose and CVD/Events: Correlation or Causality?

Pharmacologic Therapy for T2DM: ADA 2018 Recommendations (4)

Summary and Conclusions

Abbreviations

Abbreviations (cont)